Research publications
Herrmann SE, McKinnon EJ, Williams LJ, John M, Mallal S, Lucas M, Nolan D. Use of alcohol, nicotine and other drugs in the Western Australian HIV Cohort Study. Sexual Health (In press)
Lee MH, Stocker SL, Anderson JA, Phillips EJ, Nolan D, Williams KM, Graham GG, Sullivan JR, O Day R. Initiating allopurinol therapy: do we need to know the patient’s HLA status? Intern Med J 2011(In press).
YongHong Zhang YanChun Peng, HuiPing Yan, Keyi Xu, Masumichi Saito, Hao Wu, XinYue Chen, Srinika Ranasinghe, Nozomi Kuse, Tim Powell, Zhao Yan, WeiHua Li, Xin Zhang, Xia Feng, Ning Li, Aleksandra Leligdowicz, XiaoNing Xu, Mina John, Masafumi Takiguchi, Andrew McMichael, Sarah Rowland-Jones* and Tao Dong2*. Multilayered defence in HLA-B51 associated HIV viral control. Journal of Immunology 2011 Jun 13. [Epub ahead of print] 11 July 15, 2011;187(2):684-91.
Keane NM, Roberts SG, Almeida CA, Krishnan T, Chopra A, Demaine E, Laird R, Tschochner M, Carlson JM, Mallal S, Heckerman D, James I, John M. High-avidity, high-IFNg-producing CD8 T-cell responses following immune selection during HIV-1 infection. Immunol Cell Biol 2011 May 17 Epub
Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, Sims S, Dempsey E, Freitas E, Lea S, McKiernan S, Norris S, Long A, Kelleher D, Klenerman P. Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut 2011 May 6
Dong T, Zhang Y, Xu KY, Yan H, James I, Peng Y, Blais ME, Gaudieri S, Chen X, Lun W, Wu H, Qu WY, Rostron T, Li N, Mao Y, Mallal S, Xu X, McMichael A, John M*, Rowland-Jones SL*. Extensive HLA-driven diversity following a narrow source HIV-1outbreak in rural China. Blood 2011 May 11 Epub. (*equal last author)
Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, La Grenade L, Carleton B, Papaluca-Amati M, Demoly P, Shear NH. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharm Ther 2011 May 11 Epub
Kostenko K, Kjer-Nielsen L, Nicholson I, Hudson F, Lucas A, Foley B, Chen K, Lynch K, Nguyen J, Wu AH, Tait BD, Holdsworth R, Mallal S, Rossjohn J, Bharadwaj M, McCluskey J. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. Tissue Antigens 2011 Apr 19 Epub.
Cote HC, Gerschenson M, Walker UA, Miro O, Garrabou G, Hammond E, Villarroya J, Giralt M, Villarroya F, Cinque P, Garcia-Arumi E, Andreu AL, Pinti M, Cossarizza A. Mitochondrion 2011 May; 11(3):520-527. Epub 2011 Feb 22.
Keane N, John M. Biomarkers of natural and vaccine immunity against HIV. Biomark Med 2011 Apr; 5(2):113-116.
Chakera A, Lucas A, Lucas M. Surrogate markers of infection: interrogation of the immune system. Biomark Med 2011 Apr; 5(2):131-148.
Gaudieri S. Biomarkers that reflect immune activation or dysfunction will be important in the management of infectious diseases. Biomark Med 2011 Apr; 5(2):109-12.
Qui W, James I, Carroll WM, Mastaglia FL, Kermode AG. HLA-DR allele polymorphism and multiple sclerosis in Chinese populations: a meta-analysis. Mult Scler 2011 Apr 17(4):382-388. Epub 2010 Dec 21.
Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011 Mar; 127(3 Suppl):S60-6.
Olcaydu D, Rumi E, Harutyunyan A, Passamonti F, Pietra D, Pacutto C, Berg T, Jager R, Hammond E, Cazzola M, Kralovics R. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica 2011 Mar; 96(3): 367-74. Epub 2010 Dec 20.
Law MG, Woolley I, Templeton DJ, Roth N, Chuah J, Mulhall B, Canavan P, McManus H, Cooper D, Petoumenos K & the Australian HIV Observational Database (AHOD) (incl Nolan D). J Int AIDS Soc 2011 Feb 23;14:10
Morahan G, Mehta M, James I, Chen WM, Concannon P, Akolkar B, Erlich HA, Hilner JE, Julier C, Nerup J, Nierras C, Pociot F, Todd JA, Rich SS, and the Type 1 Diabetes Genetics Consortium. Tests for genetic interactions in type 1 diabetes: linkage and stratification analyses of 4,422 affected sib-pairs. Diabetes 2011 Mar; 60(3):1030-1040. Epub 2011 Jan 24.
Merani S, Petrovic D, James I, Chopra A, Cooper D, Freitas E, Rauch A, di Iulio J, John M, Lucas M, Fitzmaurice K, McKiernan S, Norris S, Kelleher D, Klenerman P, Gaudieri S. Effect of immune pressure on hepatitis C virus evolution: Insights from a single-source outbreak. Hepatology 2011 Feb; 53(2): 396-405. Epub 2011 Jan 18
Pfafferott K, Gaudieri S, Ulsenheimer A, James I, Heeg M, Nolan D, John M, Rauch A, Mallal S, Lucas A, Klenerman P, Diepolder HM, Lucas M. Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS One 2011 Feb 8;6(2):e16797
Hertz T, Nolan D, James I, John M, Gaudieri S, Phillips E, Huang JC, Riadi G, Mallal S, Jojic N. Mapping the landscape of host-pathogen co-evolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol 2011 Feb;85(3):1310-21. Epub 2010 Nov 17
Qui W, Raven S, James I, Luo Y, Wu J, Castley A, Christiansen FT, Carroll WM, Mastaglia FL, Kermode AG. Spinal cord involvement in multiple sclerosis: a correlative MRI and high-resolution HLA-DRB1 genotyping study. J Neurol Sci 2011 Jan 15;300(1-2):114-9.
2010
Hammond E, Lucas A, Lucas M, Phillips E, Gaudieri S. Vaniprevir. Drugs of the Future 2010 35(10): (no further info avail)
Smyth RP, Schlub TE, Grimm A, Venturi V, Chopra A, Mallal S, Davenport MP, Mak J. Reducing chimera formation during PCR amplification to ensure accurate genotyping. Gene 2010 Dec 1;469(1-2):45-51. Epub 2010 Sep 9
Martin A, Amin J, Cooper DA, Carr A, Kellher AD, Bloch M, Baker D, Woolley I, Emery S, STEAL Study Group (incl Nolan D). Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010 Nov 13; 24(17):2657-63
The International HIV Controllers Study (incl John M). The major determinants of HIV-1 control affect HLA Class I peptide presentation. Science 2010 Dec 10;330(6010):1551-7. Epub 2010 Nov 4.
Iwabu Y, Kinomoto M, Tasumi M, Fujita H, Shimura M, Tanaka Y, Ishizaka Y, Nolan D, Mallal S, Sata T, Tokunaga K. Differential anti-APOBEC3G activity of HIV-1 vif proteins derived from different subtypes. Journal of Biological Chemistry 2010 Nov 12;285(46):35350-8. Epub 2010 Sep 10
Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD Study Group (incl Nolan D, Mallal S). Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010 Oct; 17(5):491-501.
Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010 Sep 1; 51(5):591-599. Epub 2010 Jul 20.
Rohrbach J, Robinson N, Harcourt G, Hammond E, Gaudieri S, Gorgievski M, Telenti A, Keiser O, Gunthard HF, Hirschel B, Hoffmann M, Bernasconi E, Battegay M, Furrer H, Klenerman P, Rauch A; the Swiss HIV Cohort Study. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010 Sep 59(9):1252-1258. Epub 2010 Jul 26.
Almeida CA, Roberts S, Laird R, Ahmad I, Cooper D, McKinnon E, Chopra A, Heckerman D, Mallal S, John M. Exploiting knowledge of immune selection in HIV-1 to detect HIV-specific CD8 T-cell responses. Vaccine 2010 Aug 23; 29 (37):6052-6057. Epub 2010 Jul 7.
Hammond T, Lee S, Watson MW. Flexman JP, Cheng W, Fernandez S, Price P. Toll-like receptor (TLR) expression on CD4+ and CD8+ T-cells in patients chronically infected with hepatitis C virus. Cell Immunol 2010; 264(2): 150-155. Epub 2010 Jun 8.
Qiu W, Wu JS, Castley A, James I, Joseph J, Christiansen FT, Carroll WM, Mastaglia FL, Kermode AG. Clinical profile and HLA-DRB1 genotype of late onset multiple sclerosis in Western Australia. J Clin Neurosci 2010 Aug; 17(8):1009-13. Epub 2010 May 23.
Lee S, Hammond T, Watson MW, Flexman JP, Cheng W, Fernandez S, Price P. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy? Clin Exp Immunol 2010 Jul 1; 161(1): 118-26. Epub 2010 Apr 9.
Hillner JE, Perdue LH, Sides EG, Pierce JJ, Wagner AM, Aldrich A, Loth A, Albret L, Wagenknecht LE, Nierras C, Akolkar B and T1DGC (incl Gaudieri S, James I, McKinnon E, Nolan D). Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC). Clinical Trials 2010;7 (1 Suppl) S5-S32. Epub 2010 Jul 5.
Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010 Jul (11(7):973-87
Falster K, Wand H, Donovan B, Anderson J, Nolan D, Watson K, Watson J, Law MG on behalf of the Australian HIV Observational Database. Hospitalizations in a cohort of HIV patients in Australia, 1999-2007. AIDS 2010 Jun 1; 24(9):1329-1339.
Lucas M, Nicol P, McKinnon E, Whidborne R, Lucas A, Thambiran A, Burgner D, Waring J, French M. A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax 2010 May 65(5):442-448.
John M, Heckerman D, James I, Park LP, Carlson JM, Chopra A, Gaudieri S, Nolan D, Haas DW, Riddler SA, Haubrich R, Mallal S. Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol 2010 Apr 15;184(8):4368-77. Epub 2010 Mar 15
Lee S, Watson MW, Flexman JP, Cheng W, Hammond T, Price P. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy. J Med Virol 2010 Apr;82(4):568-574.
Wu J-S, James I, Qui W, Castley A, Christiansen FT, Carroll WM, Mastaglia FL, Kermode AG. Influence of HLA-DRB1 allele heterogeneity on disease risk and clinical course in West Australian MS cohort: a high-resolution genotyping study. Mult Scler 2010 May; 16(5):526-32. Epub 2010 Mar 5.
Qui W, Bundell C, Wu JS, Castley A, James I, Hollingsworth P, Christiansen F, Carroll WM, Mataglia FL, Kermode AG. Low level of systemic autoimmunity in Western Australian multiple sclerosis patients. Mult Scler 2010 16(3):351-354. Feb 11 Epub
Wu J-S, Qui W, Castley A, James I, Mastaglia F, Christiansen F, Carroll WM, Joseph J, Kermode AG. (2009). Modifying effects of HLA-DRB1 allele interactions on age-at-onset of multiple sclerosis in Western Australia. Multiple Sclerosis Mult Scler 2010 Jan; 16(1):15-20. Epub 2009 Dec 7
Wu J-S, Qui W, Castley A, James I, Joseph J, Christiansen F, Carroll WM, Mastaglia FL, Kermode AG. (2009). Presence of CSF oligoclonal bands (OCB) is associated with the HLA-DRB1 genotype in a West Australian multiple sclerosis cohort. J Neurol Sci 2010 Jan 15;288(1-2):63-67. Epub 2009 Oct 30.
Wu JS, James I, Qui W, Castley A, Christiansen FT, Carroll WM, Mastaglia FL, Kermode AG. HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia. J Neuroimmun 2010 219:109-113.
Worm SW, Friis-Moller N, Bruyand M, D’Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C, D:A:D Study Group (incl Mallal S). High prevalence of the metabolic syndrome in HIV-infected patients impact of different definitions of the metabolic syndrome. AIDS 2010 Jan 28;24(3):427-35.
Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV Controllers Study (Incl John M), Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet. 2010 Jan;86(1):88-92. Epub 2009 Dec 31.
2009
Morahan G, McKinnon E, Browning B, Julier C, Pociot F, James I, and the Type I Diabetes Genetics Consortium. Evaluation of IL12B as a candidate diabetes susceptibility gene using data from the Type 1 Diabetes Genetics Consortium. Genes Immun 2009 Dec;10 Suppl 1:S64-68.
Li S, Floess S, Hamann A, Gaudieri S, Lucas A, Hellard M, Roberts S, Paukovic G, Plebanski M, Loveland BE, Aitken C, Barry S, Schofield L, Gowans EJ. Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog 2009 Dec;5(12):e1000707. Epub 2009 Dec 24.
Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Gunthard HF, Mallal S, Martinez-Picado J, Miro JM, Obel N, Descombes P, Antonarakis SE, Beckmann JS, O’Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A, Goldstein DB for the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009 Dec;5(12):e1000791. Epub 2009 Dec 24
Tschochner M, Chopra A, Maiden T, Ahmad I, James I, Furrer H, Guntard HF, Mallal S, Rauch A, John M. Effects of HIV-1 immune selection on susceptibility to integrase inhibitor resistance. Antivir Ther 2009;14(7):953-964.
Rauch A, Gaudieri S, Thio C, Bochud P-Y. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009 Nov; 10(11):1819-37
Humpreys I, Fleming V, Fabris P, Parker J, Schulenberg B, Brown A, Demetriou C, Gaudieri S, Pfafferott K, Lucas M, Collier J, Huang KH, Pybus OG, Klenerman P, Barnes E. Full length characterisation of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection. J Virol 2009 Nov 83(22):11456-66. Sep 9 EPUB
Falster K, Choi JY, Donovan B, Duncombe C, Mullhall B, Sowden D, Zhou J, Law MG; Australian HIV Observational Database; TREAT Asia HIV Observational Database (Incl Mallal S, Nolan D). AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS 2009 Nov 13;23(17):2323-36
Mastaglia F, Needham M, Scott, James I, Zilko P, Day, Kiers, Corbett, Witt CS, Allcock R, Laing N, Garlepp M, Christiansen F. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscular Disorders 2009 Nov;19(11):763-765. Aug 31 EPUB
Phillips E, Mallal S. Personalizing antiretroviral therapy: is it a reality. Personalized Medicine 2009; 6(4):393-408
Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, Baker R, Freitas E, Humphreys I, Furrer H, Gunthard HF, Hirschel B, Mallal S, John M, Lucas M, Barnes E, Gaudieri S. Divergent adaptation of Hepatitis C virus genotypes 1 and 3 to HLA-restricted immune pressure. Hepatology 2009 Oct;50(4):1017-29. May 29 Epub
Chaubey SK, Sinha AK, Phillips E, Russell DB, Falhammar H. Transient Cardiac Arrhythmias Related to Lopinavir-Ritonavir In Two Patients with HIV Infection. Sexual Health 2009 Sep; 6(3): 254-257
Kesselring Am, Wit FW, Sabin CA, Lungren JD, Gill MJ, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A, on behalf of the Nevirapine Toxicity Multicohort Collaboration (incl Phillips E). Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009 Aug 24;23(13):1689-99.
Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman M, Swenson L, Tao I, Szeto S, Rosato P, Sela J, Kadie C, Frahm N, Brander C, Riddler S, Haubrich R, Walker B, Harrigan PR, Heckerman D, Mallal S. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS ONE 2009 Aug 19; 4(8):e6687-.
Avila-Rios S, Ormsby CE, Carlson JM, Valenzuela-Ponce H, Garrido-Rodriguez D, Blanco-Heredia J, Garcia-Morales C, Heckerman D, Brumme ZL, Mallal S, John M, Espinoza E, Reyes-Teran G. Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. Retrovirology 2009 Aug 10 6(1):72
D’Orsogna L, Wright MP, Krueger RG, McKinnon EJ, Buffery SI, Witt CS, Staples N, Loh R, Cannell PK, Christiansen FT, French MA. Allogeneic haemopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol Blood Marrow Transplant 2009 Jul; 15(7):795-803
Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS and the Type 1 Diabetes Genetics Consortium (incl Gaudieri S, James I, McKinnon E, Nolan D). Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009 Jun; 41 (6):703-7. Epub 2009 May 10.
Price P, James I. IL1A alleles associate with a virological response to antiretroviral therapy in HIV patients beginning therapy with advanced disease. AIDS 2009 Jun 1; 23(9):1173-1176.
Phillips E, Mallal S. HLA Loci and drug-induced toxicity. Current Opinion in Molecular Therapeutics 2009; 11(3):231-242
Nolan D. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci 2009;46(3):153-65
Almeida CA, Roberts S, Laird R, McKinnon E, Ahmad I, Pfafferott K, Turley J, Keane NM, Lucas A, Rushton B, Chopra A, Mallal S, John M. Automation of the ELISpot assay for high throughput detection of antigen-specific T cell responses. J Immunol Methods 2009 May 15;344(1):1-5.
Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, Falster K, Zhou J, Law MG, Asia Pacific HIV Observational Database (APHOD) (incl S Mallal, D Nolan). Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database. J Acquir Immune Defic Syndr 2009 Apr 15;50(5):513-20.
Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA,Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M (incl Phillips E). Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009 Apr 15;48(8):1138-51.
Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanga H, Fujiwara M, Hachiya A, Koizumi H, Juse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme Z, Brumme CJ, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG, Klenerman P, Ndung’u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M, Goulder P. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009 Apr 2; 458(7238):641-5.
Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaugan G, Shackel N, Jeffrey GP, Mollison L, Baker R, , Furrer H-J, Gunthard HF, Humphries I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M. Hepatitis C virus drug resistance and immune-driven adaptations: relevance new anti-viral therapy. Hepatology 2009 Apr;49(4):1069-82.
Phillips E, Mallal S. Successful translation of pharmacogenetics into the Clinic: the abacavir example. Mol Diagn Ther 2009;13(1)1-9.
Miura T, Brumme CJ, Brockman MA, Brumme ZL, Pereya F, Block BL, Trocha A, John M, Mallal S, Harrigan R, Walker BD. HLA associated viral mutations are common in human immunodeficiency virus type 1 elite controllers but significantly more frequent in chronic progressors. J Virol 2009 Apr; 83(7):3407-12. Epub Jan 19.
Falster K, Petoumenos K, Chuah J, Mijch A, Mulhall B, Kelly M, Cooper DA, Australian HIV Observational Database (incl Mallal S). Poor baseline function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. JAIDS 2009 Mar 1 ;50 (3):307-13.
Carey D, Baker D, Petoumenos K, Chuah J, Rogers GD, Watson J, Cooper DA, Emery S, Carr A, FLASH Investigators (Incl Nolan D). Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up. HIV Med 2009 Mar;10(3):163-72.
McKinnon E, Morahan G, Nolan D, James I and the Type I Diabetes Genetics Consortium. Association of MHC SNP genotype with susceptibility to Type 1 diabetes: a modified survival approach. Diabetes Obes Metab 2009 Feb; 11 Suppl 1:92-100.
Morahan G, Mehta M, McKinnon E, James I, and the Type I Diabetes Genetics Consortium. Effect of linkage status of affected sib-pairs on the search for novel Type I diabetes susceptibility genes in the HLA complex. Diabetes Obes Metab 2009 Feb; 11 Suppl 1:67-73.
James I, McKinnon E, Gaudieri S, Morahan G, and the Type I Diabetes Genetics Consortium. Missingness in the T1DGC MHC fine mapping data: Association with HLA genotype and potential influence on genetic association studies. Diabetes Obes Metab 2009 Feb; 11 Suppl 1:101-7.
Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009 Jan;94(1):38-45
2008
Martinez E, Nolan D. Long-term management of the HIV-infected patient – tailoring highly active antiretroviral therapy to optimise therapeutic outcome. Eur Infect Dis 2008 2(2):16-22.
Rauch A, Nolan D, Thurnheer C, Fux C, Cavassini M, Chave J-P, Opravil M, Phillips E, Mallal S, Furrer H & The Swiss HIV Cohort Study. Refining abacavir hypersensitivity diagnoses using structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir Ther 2008;13(8):1019-28.
Mallon PW, Sedwell R, Rogers G, Nolan D, Unemori P, Hoy J, Samaras K, Kelleher A, Emery S, Cooper DA, Carr A, Rosey Investigators. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis 2008 Dec 15;198(12):1794-803
Price P, Fernandez S, Tan D, James IR, Keane N, French MA. Nadir CD4 T-cell counts influence -interferon responses in patients who began antiretroviral treatment with <100 CD4 T-cells/l. J Acquir Imme Defic Syndr 2008 Dec 1;49(4):462-464.
Phillips E, Nolan D, Mallal S. Abacavir hypersensitivity reply to: Vandekerckhove: Blot S, Vogelaers D and Abel S, Paturel L, Cabie N. N Eng J Med 2008 358;23:2514-2516.
Hammond E, McKinnon E, Mallal S, Nolan D. Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. AIDS 2008 Nov 30;2(18):2540-3.
Herrmann S, McKinnon E, John M, Hyland N, Martinez OP, Cain A, Turner K, Coombs A, Manolikos C, Mallal S. Evidence-based, multifactorial approach to addressing non-adherence to antiretroviral therapy and improving standards of care. Intern Med J 2008 Jan; 38:8-15. Epub 2007 Oct 3.
The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group; MOnforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Frijs-Moller N, Phillips AN, Sabin CA, Lundgren JD (incl Mallal S). HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008 Oct 18;22(16):2143-53.
Kulski JK, Shigenari A, Shiina T, Ota M, Hosomichi K, James I, Inoko H. Human endogenous retrovirus (HERVK9) structural polymorphism with haplotypic HLA-A allelic associations. Genetics 2008 Sep;180(1):445-57. Epub Aug 2008.
Brumme ZL, Brumme CH, Carlson J, Streeck H, John M, Eichbaum Q, Block BL, Baker B, Kadie C, Markowitz M, Jessen H, Kelleher A, Rosenberg E, Kaldor J, Yuki Y, Carrington M, Allen TM, Mallal S, Altfeld M, Heckerman D, Walker BD. Marked epitope and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV -1 infection. J Virol 2008 Sep;82(18):9216-27. Epub 2008 Jul 9.
Needham M, James I, Corbett A, Day T, Christiansen F, Phillips B, Mastaglia FL. Sporadic inclusion body myositis: phenotypic variability and effect of HLA-DR3 in a cohort of 57 Australian cases. J of Neurol, Neurosurg Psychiatry 2008 Sep;79(9):1056-60. Epub 2008 Feb 7.
Rauch A, Gaudieri S, Evison J, Nolan D, Cavassini M, Weber R, James I, Furrer H and the Swiss HIV Cohort Study. Low current and nadir CD4-T-cell counts are associated with higher Hepatitis C viral loads in the Swiss HIV Cohort Study (SHCS). Antivir Ther 2008; 13(3):455-60.
Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, Kjer-Nielsen L, Mifsud NA, Tait BD, Holdsworth R, Almeida CA, Nolan D, Macdonald WA, Archbold JK, Kellerher AD, Marriott D, Mallal S, Bharadwaj M, Rossjohn J, McCluskey J. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008 Jun;28(6):822-32.
Almeida CA, Martin A, Nolan D, Lucas A, Cameron P, James I, Phillips E, Mallal S. Cytokine profiling in abacavir hypersensitivity patients. Antivir Ther 2008 ;13(2):281-8.
Rauch A, Nolan D, Furrer J, McKinnon E, John M, Mallal S, Gaudieri S, Gunthard HF, Schmid P, Battegay M, Hirschel B, Telenti A, James I and the Swiss HIV Cohort Study. HLA-Bw4-homozygosity is associated with an impaired CD4 T-cell recovery after initiation of highly active antiretroviral therapy (HAART). Clin Infect Dis 2008 June 46; 12:1921-1925. May 8 Epub
Shear NH, Milpied B, Bruynzeel DP, Phillips E. A review of drug patch testing and implications for HIV Physicians. AIDS 2008; 22:999-1007
Hammond E, Martin A, Nolan D, Metcalf C, Mallal S. Eruptive hemangioma associated with HIV therapy and mitochondrial pathology. Pathology 2008 Jun; 40(4):425-9
Tan DB, Yong YK, Tan HY, Kamarulzaman A, Tan LH, Lim A, James I, French M, Price P. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med. 2008 May;9(5):307-16.
Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD (incl Mallal S). Changes over time in risk factors for cardiovascular disease and use of lipid lowering drugs in HIV-infected individuals and impact on myocardial infarctions. Clin Infect Dis 2008 Apr 1;46(7):1101-10.
D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD (incl Mallal S). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008 Apr 26; 371(9622):1417-26. Epub 2008 Apr 2.
Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M for the SHAPE Study Team. High sensitivity of HLA-B*5701 in immunologically-confirmed cases of abacavir hypersensitivity in White and Black patients. Clin Infect Dis 2008; 46(1 April):1111-8.
Gaullar JP, Gallego-Escuredo JM, Domingo JC, Alegre M, Fontdevila J, Martinez E, Hammond EL, Domingo P, Giralt M, Villarroya E. Differential gene expression indicates that a ‘buffalo hump’ is a distinct adipose tissue disturbance in HIV-1 associated lipodystrophy. AIDS 2008 Mar 12; 22(5):575-84.
Needham M, Hooper A, James I, van Bockxmeer F, Corbett A, Day T, Garlepp MJ, Mastaglia FL. Apolipoprotein alleles in sporadic inclusion body myositis: a reappraisal. Neuromuscul Disord 2008 Feb;18(2):150-2 – Epub 2007 Dec 3
Northfield JW, Kasprowicz V, Lucas M, Kersting N, Bengsch B, Kim A, Phillips RE, Walker BD, Thimme R, Lauer G, Klenerman P. CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation. Hepatology 2008 Feb;47(2):396-406.
Harvey ML, Gaudieri S, Villet MH, Dadour IR. A global study of forensically significant calliphorids: implications for identification. Forensic Sci Int 2008; 177:66-76
Phillips E, Hayden A, Gutierrez S, Jahnke N, Yip B, Lima VD, Hogg RS, Harrigan PR, Montaner JSG. Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity (Authors reply). AIDS 2008, 19 Feb;22(4):548-549.
Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A, for the PREDICT-1 Study Team. HLA-B*5701 screening for abacavir hypersensitivity. New Engl J of Med 2008; Feb 7;358:568-79.
Phillips EJ, Mallal SA. Pharmacogenetics and the potential for individualization of antiretroviral therapy. Curr Opin Infect Dis 2008 Feb; 21:16-24. Review
Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR. A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther 2008 13(2):161-75.
2007
Laird R, Schneider P, Gaudieri S. Forensic STRs as potential disease markers: a study of VWA and von Willebrand’s Disease. Forensic Sci Int 2007 Dec2-4(1):253-261.
Hammond E, Almeida CA, Mamotte C, Nolan D, Phillips E, Schollaardt TA, Gill MJ, Angel JB, Neurath D, Li J, Giulivi T, McIntyre C, Koultchitski G, Wong B, Reis M, Rachlis A, Cole DE, Chew CB, Neifer S, Lalonde R, Roger M, Jeanneau A, Mallal S. External quality assessment of HLA-B*5701 reporting: an international multi-centre survey. Antivir Ther 2007; 12(7):1027-32.
Harari A, Cellerai C, Enders FB, Köstler, J, Codarri L, Tapia G, Boyman O, Castro E, Gaudieri S, James I, John M, Wagner R, Mallal S, Pantaleo G. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci USA 2007 Oct 9; 104(41):16233-8. Epub 2007 Oct 2.
D'Orsogna LJ, Krueger RG, McKinnon EJ, French MA. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS 2007 Aug 20; 21(13):1747-52.
Raboud J, Lesosky M, Sterling S, Phillips E, Walmsley S, Bayoumi A. An estimate of the proportion of symptoms reported in self-administered questionnaires that are captured as adverse events in an observational database. HIV Clin Trials 2007 Sep-Oct; 8(5):311-319.
Pocathikorn A, Taylor RR, James I, Mamotte CDS. LDL-receptor mRNA expression is down-regulated within an hour of an acute fat load and is influenced by genetic polymorphism. J Nutr 2007 Sep; 137(9):2062-7.
Frahm N, Yusim K, Suscovich TJ, Adams S, Sidney J, Hraber P, Hewitt HS, Linde CH, Kavanagh DG, Woodberry T, Henry LM, Faircloth K, Listgarten J, Kadie C, Jojic N, Sango K, Brown NV, Pae E, Zaman MT, Bihl F, Khatri A, John M, Mallal S, Marincola FM, Walker BD, Sette A, Heckerman D, Korber BT, Brander C. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 2007 Sep;37(9):2419-33.
Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis S, Letvin NL, McMichael A, Haynes BF, Telenti A, Goldstein DB. Identification of major determinants of the host control of HIV-1 through a whole genome association study. Science 2007 Aug 17; 317(5840) L944-7 – Epub Jul 19.
Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007 Aug; 7(4):324-30. Review.
Lim A, Tan D, Price P, Kamarulzaman A, Tan HY, James I, French MA. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and do not resolve after one year on ART. AIDS 2007 Jul 31; 21(12):1525-34.
Phillips EJ, Gutierrez S, Jahnke N, Yip B, Lima VD, Hogg RS, Harrigan PR, Montaner JSG. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug naïve HIV-positive patients. AIDS 2007 Jul31; 21(12):1561-8.
Lucas M, Ulsenheimer A, Pfafferott K, Heeg MH, Gaudieri S, Gruner N, Rauch A, Gerlach JT, Jung MC, Zachoval R, Pape GR, Schraut W, Santantonio T, Nitschko H, Obermeier M, Phillips R, Scriba TJ, Semmo N, Day C, Weber JN, Fidler S, Thimme R, Haberstroh A, Baumert TF, Klenerman P, Diepolder HM. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS ONE 2007 Jul25;2:e649
Carlson J, Kadie C, Mallal S, Heckerman D. Leveraging hierarchical population structure in discrete association studies. PLoS ONE 2007 Jul 4;2:e591.
Hammond E, Nolan D. Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy. Curr Opin HIV AIDS 2007; 2(4): 274-281
Nolan D. The view from Sydney: 9th International Lipodystrophy Workshop. Nutrition & Metabolic Dis in HIV Infection 2007 July-September Quarterly; VI(3).
Hammond E, Mamotte C, Nolan D, Mallal S. "HLA-B*5701 Typing: Evaluation of an Allele-Specific PCR Melting Assay." Tissue Antigens 2007 Jul: 70(1 0:58-61
Mallal S, Phillips E. Introduction of pharmacogenetic screening to HIV clinical practice: potential benefits and challenges. Eur Infect Dis 2007;1 (June): 13-18.
Martin AM, Almeida C-A, Cameron P, Purcell AW, Nolan D, James I, McCluskey J, Phillips E, Landay A, Mallal S. Immune responses to abacavir in antigen presenting cells from hypersensitive patients. AIDS 2007 Jun; 21(10):1233-44.
Flatau P, James I, Watson R, Wood G, Hendershott P. Leaving the parental home in Australia over the generations: Evidence from the Household, Income and Labour Dynamics in Australia (HILDA) survey. J Population Res 2007 May ;24(1):51-71.
Langan LL, Park LP, Hughes TL, Irish A, Luxton G, Witt CS, Christiansen FT. Post-transplant HLA Class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transpl 2007 Apr; 7(4):847-56.
Rauch A, Laird R, McKinnon E, Telenti A, Furrer H, Weber R, Smillie D, Gaudieri S, the Swiss HIV Cohort Study. Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens 2007 Apr; 69 Suppl 1:237-40.
French M, Keane N, McKinnon E, Phung S, Price P. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells. HIV Med 2007 Apr; 8(3):148-55.
Wu JH, Ward NC, Indrawan AP, Almeida CA, Hodgson JM, Proudfoot JM, Puddey IB, Croft KD. Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes. Clin Chem 2007 Mar; 53(3):511-9. Epub 2007 Feb 1.
Hammond E, Shaw K, Herrmann R. The JAK2V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disorders. Leukemia 2007 Apr; 21(4):815-6, discussion 816-8. E pub 2007 Feb 1.
Hammond E, Shaw K, Herrmann R. “The JAK2V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disorders” by El Housni et al. Leukemia 2007 Apr; 21(4):817-8. E pub 2007 Feb 1.
Lucas A, Nolan D, Mallal S. HLA*B5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007 Apr; 59(4):591-3. Epub 2007 Feb 22.
Hammond E, Shaw K, Carnley B, P'ng S, James I, Herrmann R. Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. J Mol Diagn 2007 Apr; 9(2):242-8.
Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, Kadie C, Carlson J, Yusim K, McMahon B, Gaschen B, Mallal S, Mulins JI, Nickle DC, Herbeck J, Rousseau C, Learn GH, Miura T, Brander C, Walker B, Korber B. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007 Mar 16; 315(5818):1583-6.
Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, Frahm N, Feeney ME, Tang Y, Pereyra F, Labute MX, Pfafferott K, Leslie A, Crawford H, Allgaier R, Hildebrand W, Kaslow R, Brander C, Allen TM, Rosenberg ES, Kiepiela P, Vajpayee M, Goepfert PA, Altfeld M, Goulder PJ, Walker BD. Mutually exclusive T cell receptor induction and differential susceptibility to HIV-1 mutational escape associated with a two amino acid difference between HLA class I subtypes. J Virol 2007 Feb; 81(4):1619-31 – Epub 2006 Nov22.
Gabutero E, Moore C, Mallal S, Stewart G, Williamson P. Interaction between allelic variation in IL12B and CCR5 affects the development of AIDS: IL12B/CCR5 interaction and HIV/AIDS. AIDS 2007 Jan 2; 21(1):65-9.
Tansey C, Louie M, Loeb M, Gold W, Muller M, deJager J, Cameron J, Tomlinson G, Mazzulli T, Walmsley S, Rachlis A, Mederski B, Silverman M, Shainhouse Z, Ephtimios I, Avendano M, Downey J, Styra R, Yamamura D, Gerson M, Standbrook M, Marras T, Phillips E, Zamel N, Richardson S, Slutsky A, Herridge M. One-year outcomes and health-care utilization in survivors of severe acute respiratory syndrome (SARS). Arch Intern Med 2007; 167:1312-20.
Chui CK, Brumme ZL, Brumme CJ, Yip B, Phillips EJ, Montaner JS, Harrigan PR. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis 2007; 44:1503-8.
Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus decolonization. Clin Infect Dis 2007; 44(2):178-85.
2006
Komatsu H, Inui A, Sogo T, Fujisawa T, Nagasaka H, Nonoyama S, Sierro S, Northfield J, Lucas M, Vargas A, Klenerman P. Large scale analysis of pediatric antiviral CD8+ T cell populations reveals sustained, functional and mature responses. Immun Ageing 2006 Dec 8; 3:11.
Tang P, Walsh S, Murray C, Alterman C, Varia M, Broukhanski G, Chedore P, DeKoven J, Assaad D, Gold W, Ghazarian D, Finkelstein M, Pritchard M, Yaffe B, Jamieson F, Henry B, Phillips E. Outbreak of acupuncture-associated cutaneous Mycobacterium abscessus infections. J Cut Med and Surg 2006; 10(4):166-9.
Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, Cheng W, Pfafferott K, Naidoo K, Chapman R, Battegay M, Weber R, Telenti A, Furrer H, James I, Lucas M, Mallal SA. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 2006 Nov; 80(22):11094-104. Erratum in J Virol 2007 Aug; 81(16)8846-8.
Lucas M, Ulsenheimer A, Seth NP, Tilman Gerlach J, Gruener NH, Louhgry A, Pape GR, Wucherpfenning KW, Diepolder HM, Klenerman P. Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses. J Viral Hepat 2006 Oct; 13(10):708-14.
Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S. Population level analysis of human immunodeficiency virus Type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 2006 Sep; 80(18):9259-69. Erratum in J Virol 2007 Aug; 81(16)8843-5.
Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gene A, Fuller SJ, Nolan D, Gandy SE, Martins RN. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006 Aug 11 (8):721-36. Epub Jun 20
Cherry CL, Nolan D, James IR, McKinnon EJ, Mallal SA, Gahan ME, Lal L, McArthur JC, Wesselingh SL. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr 2006 Aug 1; 42(4):435-40.
Nolan D, Gaudieri S, Mallal S. Host genetics and viral infections: immunology taught by viruses, virology taught by the immune system. Curr Opin Immunol 2006 Aug; 18(4):413-21. Epub 2006 Jun 13. Review.
Frater AJ, Edwards CT, McCarthy N, Fox J, Brown H, Milicic A, Mackie N, Pillay T, Drijfhout JW, Dustan S, Clarke JR, Holmes EC, Zhang HT, Pfafferott K, Goulder PJ, McClure MO, Weber J, Phillips RE, Fidler S. Passive sexual transmission of human immunodeficiency virus type 1 variants and adaptation in new hosts. J Virol 2006 Jul; 80(14):7226-34.
Price P, Keane NM, Lee S, Lim AF, McKinnon EJ, French MA. A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy. Immunology 2006 Sept; 119(1):74-82. Epub 2006 Jun 22.
Fernandez S, Price P, McKinnon EJ, Nolan RC, French MA. Low CD4(+) T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4(+) T-cell activation and senescence but not with lower effector memory T-cell function. Clin Immunol 2006 Aug; 120(2):163-70. Epub 2006 Jun 9.
Phillips E. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 2006; 43; 103-5.
Phillips E. The pharmacogenetics of antiretroviral therapy. Curr Opin HIV AIDS 2006; 1:249-56.
Semmo N, Lucas M, Krashias G, Lauer G, Chapel H, Klenerman P. Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. Blood 2006 Jun 1; 107(11):4570-1.
Mallal S. Host genetics unplugged: removing the camouflage of viral adaptations. Curr Opin HIV AIDS 2006 1(3):218-219.
Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006 Jul 1; 43(1):99-102. Epub 2006 May 26.
Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics 2006; May; 16(5):353-7.
Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD, Stuart DI, Kiepiela P, Goulder P. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006 Apr; 80(7):3617-23.
Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, Yusim K, Woodberry T, Sango K, Hewitt HS, Henry L, Linde CH, Chisholm JV 3rd, Zaman TM, Pae E, Mallal S, Walker BD, Sette A, Korber BT, Heckerman D, Brander C. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006 Apr 1; 176(7):4094-101.
Burgess K, Price P, James IR, Stone SF, Keane NM, Lim AY, Warmington JR, French MA. Interferon-gamma responses to Candida recover slowly or remain low in immunodeficient HIV patients responding to ART. J Clin Immunol 2006 Mar; 26(2):160-7. Epub 2006 Mar 28.
Nolan D, Phillips E, Mallal S. Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infect Dis 2006 Feb 1; 42(3):408-10. Epub 2005 Dec 27.
Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, Sango K, Feeney ME, Addo MM, Lichterfeld M, Lahaie MP, Pae E, Wurcel AG, Roach T, St John MA, Altfeld M, Marincola FM, Moore C, Mallal S, Carrington M, Heckerman D, Allen TM, Mullins JI, Korber BT, Goulder PJ, Walker BD, Brander C. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006 Feb; 7(2):173-8. Epub 2005 Dec 20.
Fernandez S, Rosenow AA, James IR, Roberts SG, Nolan RC, French MA, Price P. Recovery of CD4+ T Cells in HIV patients with a stable virologic response to antiretroviral therapy is associated with polymorphisms of interleukin-6 and central major histocompatibility complex genes. J Acquir Immune Defic Syndr 2006 Jan 1; 41(1):1-5.
Martin A, Nolan D, Almeida CA, Rauch A, Mallal S. Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics 2006 Jan; 7(1):15-23. Review.
Hammond E. Review of the 7th International Workshop on Adverse Reactions and Lipodystrophy in HIV, Dublin 2005. Nutrition & Metabolic Disorders of HIV infection 2006 1:899-909
2005
Balakrishnan K, Verdile G, Mehta PD, Beilby J, Nolan D, Galvao DA, Newton R, Gandy SE, Martins RN. Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis 2005 Dec; 8(3):269-82.
Nolan D, Mallal S. Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sex Health 2005; 2(3):153-63. Review.
Vidal F, Vilades C, Domingo P, Broch M, Pedrol E, Dalmau D, Knobel H, Peraire J, Gutierrez C, Sambeat MA, Fontanet A, Deig E, Cairo M, Montero M, Richart C, Mallal S on behalf of the Chemokines LNTP Study Group. Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 2491 variant allele. J Acquir Immune Defic Syndr 2005 Dec 15; 40(5):527-31.
Suter R, McKinnon E, Perkins N, Besier R. The effective life of ivermectin on Western Australian sheep farms - a survival analysis. Prev Vet Med 2005 Dec 12; 72(3-4):311-22. Epub 2005 Sep 23.
Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'Sullivan KM, Desouza I, Feeney ME, Eldridge RL, Maier EL, Kaufmann DE, Lahaie MP, Reyor L, Tanzi G, Johnston MN, Brander C, Draenert R, Rockstroh JK, Jessen H, Rosenberg ES, Mallal SA, Walker BD. Selective escape from CD8+ T-Cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005 Nov; 79(21):13239-49.
Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, Cheng M, Allgaier RL, Mui S, Frahm N, Alter G, Brown NV, Johnston MN, Rosenberg ES, Mallal SA, Brander C, Walker BD, Altfeld M. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 2005 Oct; 79(20):12952-60.
Redgrave BE, Stone SF, French MAH, Krueger R, James I, Price P. The effect of combination antiretroviral therapy on CD5+ B-cells, B-cell activation and hypergammaglobulinemia in HIV-1 patients. HIV Med 2005 Sep; 6:307-12.
Gaudieri S, Desantis D, McKinnon E, Moore C, Nolan D, Witt CS, Mallal SA, Christiansen FT. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005 Dec; 6(8):683-90.
John M, Moore CB, James IR, Mallal SA. Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1. Antivir Ther 2005; 10(4); 551-5.
Lucas AD, Gaudieri S, Rauch A, Nolan D and Mallal S. Cellular tropism of HIV-1 mediated and constrained by co-receptor dependencies. Journal of Viral Entry 2005 Vol 1 No1 17-27.
Nolan D. Do non nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? Drug Safety 2005 28(12):1069-74.
Lucas M, Lauer GM, Timm J, Ouchi K, Kim AY, Day CL, Schulze Zur Wiesch J, Paranhos-Baccala G, Sheridan I, Casson DR, Reiser M, Gandhi RT, Li B, Allen TM, Chung RT, Klenerman P, Walker BD. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 2005 Oct; 79(20):12979-88.
Laird R, Dawkins RL, Gaudieri S. Use of the genomic matching technique to complement multiplex STR profiling reduces DNA profiling costs in high volume crimes and intelligence led screens. Forensic Sci Int 2005 Jul 16; 151(2-3):249-57. Epub 2005 Apr 21.
Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, Alexander GJ. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 2005 Jun; 79(12):7852-9.
Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, Trocha A, Yu XG, Verrill C, Allen T, Moore C, Mallal S, Burchett S, McIntosh K, Pelton SI, St John MA, Hazra R, Klenerman P, Altfeld M, Walker BD, Goulder PJ. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol 2005; Jun 15; 174(12): 7524-30.
Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, Martin AM, Mallal SA, Shear NH. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; June10; 19(9): 979-81.
Martin AM, Nolan D, Mallal S. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens 2005; Jun; 65(6): 571-4.
Semmo N, Day CL, Ward SM, Lucas M, Harcourt G, Loughry A, Klenerman P. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005 May; 41(5):1019-28.
Northfield J, Lucas M, Jones H, Young NT, Klenerman P. Does memory improve with age? CD85j (ILT-2/LIR-1) expression on CD8 T cells correlates with 'memory inflation' in human cytomegalovirus infection. Immunol Cell Biol 2005 Apr; 83(2):182-8.
Ogasawara M, Imanishi T, Moriwaki K, Gaudieri S, Tsuda H, Hashimoto H, Shiroishi T, Gojobori T, Koide T. Length variation of CAG/CAA triplet repeats in 50 genes among 16 inbred mouse strains. Gene 2005 Apr 11; 349:107-19.
Gillett MJ, Cameron PU, Nguyen HV, Hurley DM, Mallal SA. Iatrogenic Cushing's syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone. AIDS 2005; 19(07): 740-1.
Nolan D. Face to face with lipoatrophy. An interview with David Nolan by Nelson Vergel. GMHC Treat Issues 2005 Mar-Apr; 19(3-4):1-6.
Nolan D, Reiss P, Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 2005 Mar; 4(2):201-18. Review.
Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, Hilton L, Thobakgale C, Ramduth D, Draenert R, Le Gall S, Luzzi G, Edwards A, Brander C, Sewell AK, Moore S, Mullins J, Moore C, Mallal S, Bhardwaj N, Yusim K, Phillips R, Klenerman P, Korber B, Kiepiela P, Walker B, Goulder P. Transmission and accumulation of CTL escape variants drives negative associations between HIV polymorphisms and HLA. J Exp Med 2005; Mar21; 201(6): 891-902.
Nolan D, James I, Mallal S. HIV/AIDS. HIV: experiencing the pressures of modern life. Science 2005; Mar 4; 307(5714): 1422-4.
John M, Mallal S. CTL responses to HIV and SIV: wrestling with smoke. Nat Immunol 2005; Mar; 6(3): 232-4.
Gaudieri S, Nolan D, McKinnon E, Witt CS, Mallal S, Christiansen FT. Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses. Mol Immunol 2005; Feb; 42(4): 557-60. Review.
Kim AY, Lauer GM, Ouchi K, Addo MM, Lucas M, Schulze Zur Wiesch J, Timm J, Boczanowski M, Duncan JE, Wurcel AG, Casson D, Chung RT, Draenert R, Klenerman P, Walker BD. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T cell count in HIV-1 co-infected individuals. Blood 2005 Feb 1; 105(3):1170-8.
Scriba TJ, Zhang HT, Brown HL, Oxenius A, Tamm N, Fidler S, Fox J, Weber JN, Klenerman P, Day CL, Lucas M, Phillips RE. HIV-1 specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. J Clin Invest 2005 Feb; 115(2):443-50.
Northfield JW, Harcourt G, Lucas M, Klenerman P. Immunology of viral co-infections with HIV. Arch Immunol Ther Exp (Warsz). 2005 Jan-Feb; 53(1):3-12 Review.
Martin A, Nolan D, James I, Cameron P, Keller J, Moore C, Phillips E, Christiansen FT, Mallal S. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4+ T cell counts. AIDS 2005; Jan 3; 19(1): 97-9.
2004
Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004; Dec; 9(6):849-63. Review.
Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, Pillay T, Ouchi K, Reyor LL, Zur Wiesch JS, Ghandhi RT, Chung RT, Bhardwaj N, Klenerman P, Walker BD, Allen TM. CD8 epitope escape and reversion in acute HCV infection. J Exp Med 2004 Dec 20; 200(12):1593-604.
Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale D, Chetty S, Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber L, Szinger J, Day C, Klenerman P, Mullins J, Korber B, Walker BD, Goulder PJR. Dominant influence of HLA-B in medicating the potential co-evolution of HIV and HLA. Nature 2004; Dec 9; 432(7018):769-75.
Windsor L, Morahan G, Huang D, McCann V, Jones T, James I, Christiansen F, Price P. Alleles of the IL2B3’UTR associate with late onset type diabetes. Hum Immunol 2004; Dec; 65(12):1432-6.
Keane NM, Price P, Lee S, Almeida CA, Stone SF, James IR, French, MA. Restoration of CD4 T-cell responses to cytomegalovirus is short lived in severely immunodeficient HIV patients responding to HAART. HIV Med 2004; Nov; 5(6):407-14.
Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, Klenerman P. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterol 2004 Sep; 127(3):924-36.
Martin A, Nolan D, Gaudieri S, Phillips E, Mallal S. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics 2004; Sep; 5(6): 643-55. Review.
Collaboration of HIV Cohorts – (Writing Committee – Phillips A, Ledergerber B, Lundgren J, Hogg R, d’Arminio Monforte A, Castelli F, Wlker S, Staszewski S, Dabis F, Gazzard B, Saag M, Petoumenous K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M, Costagliola D. Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. J Infect Dis 2004 Aug 15;190(4):675-87 (Epub 2004 Jul 19)
McLure CA, Dawkins RL, Williamson JF, Davies RA, Berry J, Laird NL, Gaudieri S. Amino acid patterns within short consensus repeats define conserved duplicons shared by genes of the RCA complex. J Mol Evol 2004 Aug; 59(2):143-57.
Martin A, Smith D, Carr A, Hoy J, Chuah J, Mallal S, Law M, Clements M, Cooper DA. Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (The PIILR Study). HIV Clin Trials 2004 Jul-Aug; 5(4):192-200.
MS2004-05 – Refman 7583 - PDF
Nolan D, Pace C. Potential roles for uncoupling proteins in HIV lipodystrophy. Mitochondrion 2004; Jul; 4:185-191.
MS2003-19 – Refman 7414 - PDF
Price P, James I, Fernandez S, French MA. Alleles of the gene encoding IL-1alpha may predict control of plasma viraemia in HIV-1 patients on highly active antiretroviral therapy. AIDS 2004 Jul 23; 18(11):1495-501.
Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, Le Gall S, John M, Mothe BR, Lee PK, Kalife ET, Cohen DE, Freedberg KA, Strick DA, Johnston MN, Sette A, Rosenberg ES, Mallal SA, Goulder PJ, Brander C, Walker BD. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 2004 Jul; 78(13):7069-78.
Harcourt GC, Lucas M, Sheridan I, Barnes E, Phillips R, Klenerman P. Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes. J Viral Hepat 2004 Jul; 11(4):324-31.
Lucas M, Day CL, Wyer JR, Cunliffe SL, Loughry A, McMichael AJ, Klenerman P. Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. J Virol 2004 Jul; 78(13):7284-7.
Nolan D, Gaudieri S, John M, Mallal S. Impact of host genetics on HIV disease progression and treatment: new conflicts on an ancient battleground. Editorial review AIDS 2004; Jun 18; 18:1231–40. Review.
Barnes E, Ward SM, Kasprowicz VO, Dusheiko G, Klenerman P, Lucas M. Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur J Immunol 2004 Jun; 34(6):1570-7.
Ward SM, Jonsson JR, Sierro S, Clouston AD, Lucas M, Vargas AL, Powell EE, Klenerman P. Virus-specific CD8+ T lymphocytes within the normal human liver. Eur J Immunol 2004 Jun; 34(6):1526-31.
Martin AM, Kulski JK, Gaudieri S, Witt CS, Freitas EM, Trowsdale J, Christiansen FT. Comparative genomic analysis, diversity and evolution of two common KIR haplotypes A and B. Gene 2004; Jun23; 335:121-131.
Nolan D, Mallal S. The role of nucleoside analogues in fat redistribution syndrome. J HIV Ther 2004; May; 9(2): 34–40. Review.
Hammond E, Nolan D, James I, Metcalf C, Mallal S. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6- 12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 2004 Mar 26; 18(5):815-7.
Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; Mar 23; 101(12):4180-5. Epub 2004 Mar15.
Lucas M, Vargas-Cuero AL, Lauer GM, Barnes E, Willberg CB, Semmo N, Walker BD, Phillips R, Klenerman P. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol 2004 Feb 1; 172(3):1744-53.
Martin AM, Gaudieri S, Witt C, Sayer D, Castley A, Mamotte C, Nolan D, James I, Christiansen F, Mallal S. (2004) Association of tumour necrosis factor promoter polymorphisms with abacavir hypersensitivity. In HLA 2004: Immunobiology of the Human MHC, John Hansen and Bo Dupont, Editors.
Burkhardt MS, Foster JK, Laws SM, Baker LD, Craft S, Gandy SE, Stuckey BG, Clarnette R, Nolan D, Hewson-Bower B, Martins RN. Oestrogen replacement therapy may improve memory functioning in the absence of APOE e4. J Alzheimers Dis 2006 6:(3):221-8.
Nolan D, Martin A, Mallal S. Genetic susceptibility to abacavir hypersensitivity syndrome. Contagion 2004; 1(1): 40-44.
2003
Nolan D, Hammond E, James I, McKinnon E, Mallal, S. Contribution of nucleoside-analogue reverse-transcriptase inhibitor therapy to lipoatrophy from the population level to the cellular level. Antivir Ther 2003; Dec; 8(6):617-26.
Telenti A, Beckmann J, Mallal S. HLA and HIV: modeling adaptation to moving targets. Pharmacogenomics J 2003; 3(5): 254-6.
Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk. QJM 2003 Nov; 96(11):825-32.
Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 2003; Aug; 8(4): 323-31.
Longman-Jacobsen N, Williamson JF, Dawkins RL, Gaudieri S. In polymorphic genomic regions indels cluster with nucleotide polymorphism: Quantum Genomics. Gene 2003 Jul 17; 312:257-61.
Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; Jul; 4(3):293-301.
Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B, Mallal S. (2003) Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; Jun 13; 17(9): 1329-38.
Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003; May; 8(2):36-41. Review.
Hammond EL, Sayer D, Nolan D, Walker U, deRonde A, Montaner J, Cote H, Gahan M, Cherry CL, Wesselingh S, Reiss P, Mallal S. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol 2003; May; 27(1): 97-110.
John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, White AJ, Mallal SA. Randomised, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; May 1; 33(1): 29-33.
Martin AM, Hammond E, Nolan D, Pace C, Den Boer M, Taylor L, Moore H, Martinez OP, Christiansen F, Mallal S. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside analogue- reverse transcriptase inhibitors. Am J Hum Genet 2003; Mar; 72(3): 549-60. Epub 2003 Feb 13. Erratum in Am J Hum Genet 2003 May; 72(5):1358.
Nolan D, Mallal S. Thymidine analogue-sparing highly active antiretroviral therapy (HAART). J HIV Ther 2003; Feb; 8(1): 2-6. Review.
McKinnon EJ, James IR, John M, Mallal SA. Viral load detectability profiles for HIV-infection. Stat Med 2003; Feb 15; 22(3): 385-96.
Harvey ML, Dadour IR, Gaudieri S. Mitochondrial DNA oxidase I gene useful in distinction between immature stages of some forensically important fly species (Diptera) in South-West Western Australia. Forensic Sci Int 2003; Jan 28; 131(2-3): 134-9.
Nolan D, Moore CM, Castley A, Sayer D, John M, James I, Mallal SA. Tumour necrosis factor-alpha gene –238G/A promoter polymorphism associated with more rapid onset of lipodystrophy. AIDS 2003; Jan 3; 17(1): 121-3.
Nolan, D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63(23): 2555-2574.
Meyer M, Gaudieri S, Rhodes DA, Trowsdale J. Cluster of TRIM genes in the human MHC class I region sharing the B30.2 domain. Tissue Antigens 2003 Jan; 61(1):63-71.
Christiansen FT, Moore CB, DeSantis D, Gaudieri S, Witt CS, James IR, Mallal SA. HLA and NK receptor genes in HIV progression. Genes and Immunity 2003; 4(24 Suppl. 1):S6-S6.
Christiansen F, John M, James I, Witt C, Mallal S. Immune escape mutations in HIV-1 sequence: the influence of HLA class I and II alleles in a host population on viral evolution. Hum Immunol 2003; 63(10 Suppl):35.
2002
Doherty DA, James IR, Newnham JP. Estimation of the Doppler ultrasound maximal umbilical waveform envelope: I. Estimation method. Ultrasound Med Biol 2002; Oct; 28(10): 1251-9.
Doherty DA, James IR, Newnham JP. Estimation of Doppler ultrasound maximal umbilical waveform envelope: II. Prediction of fetal distress. Ultrasound Med Biol 2002; Oct; 28(10): 1261-70.
Hammond EL, Lymbery A, Martin GB, Groth D, Wetherall JD. Microsatellite analysis of genetic diversity in the emu. J Heredity 2002; Sept-Oct; 93(5) 376-80.
Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; May 24; 296(5572):1439–43.
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; Mar 2; 359 (9308):727-32.
John M, Mallal S. Hyperlactatemia syndrome in people with HIV infection. Curr Opin Infect Dis 2002; Feb; 15(1): 23-9.
Martin AM, Kulski J, Witt C, Pontarotti P, Christiansen F. Leucocyte lg-like receptor cluster (LRC) in mice and men. Trends in Immunol 2002; Feb; 23(2): 81-88.
Witt CS, Whiteway JM, Warren HS, Barden A, Rogers M, Martin A, Beilin L, Christiansen F. Alleles of the KIR2DL4 receptor and their lack of association with pre-eclampsia. Eur J of Immunol 2002; Jan; 32(1):18-29.
2001
Ioannidis JPA, Rosenberg RS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, Kostrikis LG, Kuipers H, Louie L, Mallal SA, Margolick JB, Martinez OP, Meyer L, Michael NL, Operskalski E, Pantaleo G, Rizzardi GP, Schuitemaker H, Haynes W, Sheppard HW, Stewart GJ, Theodorou ID, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury JF, O’Brien TR. Effects of CCR5-32, CCR2 64I and SDF-1 3’A polymorphisms on HIV disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001; Nov6; 135(9): 782-95.
Nolan D Mallal S. Getting to the HAART of Insulin Resistance (Editorial Review). AIDS 2001; Oct 19; 15(15): 2037-41. Review.
Carr A, Chuah J, Hudson J, Mallal SA, Law M, Hoy J, Doong N, French MAH, Smith D, Cooper DA. HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, controlled, open-label, multicenter study. AIDS 2001; Sep 28; 15(14):1811-22.
Nolan D, John M, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Part 2: Concepts in aetiopathogenesis. Antivir Ther 2001; Sep; 6(3):145-60. Review.
Nolan D, Upton R, McKinnon E, John M, James I, Adler B, Roff G, Vasikaran S, Mallal SA. Stable or increasing bone mineral density in HIV-infected patients treated with Nelfinavir or Indinavir. AIDS 2001; Jul6; 15(10): 1275-80.
Nolan D, Mallal SA. Effects of sex and race on lipodystrophy pathogenesis. J HIV Ther 2001; May; 6(2): 32-6. Review.
John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, Mallal SA. Chronic hyperlactatemia in HIV- infected patients taking antiretroviral therapy. AIDS 2001; Apr 13; 15(6):717-723.
John M, Nolan D, Mallal SA. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; Mar; 6(1): 9-20. Review.
Murray R, Mallal SA, Heath C, French MAH. Cerebral mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated mycobacterium avium complex infection. Eur J Clin Microbiol Infect Dis 2001; Mar; 20(3):199-201.
de Meijer RJ, James I, Jennings P, Koeyers J. Cluster analysis of radionuclide concentrations in beach sand. Appl Radiat Isot 2001; Mar; 54(3): 535-42.
Vu HTV, Segal MR, Knuiman MW, James IR. Asymptotic and small sample statistical properties of random frailty variance estimates for shared gamma frailty models. Communications in Statistics- Simulation- and Computation 2001; 30(3): 581-95.
Rooney P, Taylor S, Couldwell D, Austin D, Block M, Quant D, Gowers A, O'Conor C, Gorton C, Allen D, Mulhall B, Mutimer K, Smith D, Keeffe N, Cooper D, Carr A, Miller J, Finlayson R, Wheatley D, Ellis D, Baker D, Kidd J, McFarlane R, Liang MT, Brown K, Petoumenos K, Law M, Smith D, Huffman S, Savage J, Morgan S, Knibbs P, Sowden D, Rawlinson M, Walker A, Orth D, Lister G, Chuah J, Fankhauser W, Dickson B, Bradford D, Wilson C, Ree H, Magon H, Fairley CK, Roth N, Eu B, Strecker S, Russell D, McGovern G, McNair R, Bal J, Daye J, Mallal S, French M, Skett J, Moore C, Maxwell D, Cain A, Medland N. Time trends in antiretroviral treatment use in Australia. Venereology - The Interdisciplinary International Journal of Sexual Health 2001; 14(4):162-168.
2000
Keane NM, Price P, Stone SF, John M, Murray RJ, French MA. Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2000; Dec 10; 16(18):1991-6.
Witt CS, Martin A, Christiansen F. Detection of KIR2DL4 alleles by sequencing and SSCP reveals a common allele with a shortened cytoplasmic tail. Tissue Antigens 2000; Sep; 56(3): 248-57.
Allcock RJN, Martin AM, Price P. The mouse as a model for the effects of MHC genes on human disease. Immunol Today 2000; Jul; 21(7):328-32.
Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; Jul7; 14(10): 1309-16.
Gillieatt SJ, Mallal S. Uptake of HIV testing and treatment in an isolated population with access to free and universal health care. Int J STD AIDS 2000; May; 11(5): 303-12.
Martin AM, Freitas EM, Witt CS, Christiansen FT. The genomic organization and evolution of the natural killer immunoglobulin-like receptor (KIR) gene cluster. Immunogenetics 2000; Apr; 51(4-5):268-280.
French MAH, Lenzo N, John M, Mallal SA, McKinnon EJ, James I, Price P, Flexman J, Tay-Kearney ML. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active anti-retroviral therapy. HIV Med 2000; Mar; 1(2):107-15.
John M, Lam M, Latham B, Saker B, French M. Nephrotic syndrome in a patient with IgA deficiency-associated mesangioproliferative glomerulonephritis. Pathology 2000; Feb; 32(1)56-58.
Nolan D, Upton R, James I, McKinnon E, John M, Mallal S. Longitudinal analysis of bone mineral density (BMD) in HIV-infected patients treated with HAART: Changes in BMD correlate with change in subcutaneous fat; with an additional independent effect of indinavir therapy to increase BMD. Antiviral Therapy 2000; 5(Suppl 5): 20.
BOOK CHAPTERS
Lucas M, Lucas A. and Gaudieri S. Mycobacterium Tuberculosis, Book 1; Chapter title: New diagnostics for Mycobacterium Tuberculosis infection; Intech-Open access Publisher, accepted for publication
Deshpande P, Lucas M., Gaudieri S. Genetic variation of host immune response genes and their effect of Hepatitis C infection and treatment outcome. Intech-Open access Publisher, accepted for publication
Phillips E, Mallal SA. (2010) HLA and Drug Reactions. In Narinder K Mehra (Ed), The HLA Complex in Biology & Medicine: A Resource Book. New Delhi, India: Jaypee Brothers Medical Publishers Pty Ltd
Phillips E, Mallal S. HLA and drug hypersensitivity. Book Chapter – The HLA Complex in Biology & Medicine – HLA and drug hypersensitivity (Chapter 20):536-565.
Nolan D, Mallal S. Lactic acidosis and other mitochondrial disorders associated with HIV therapy. Book Chapter – Section VII Approach to Specific Syndromes Chapter 74 pp1299-1310.
Uetrecht J, Phillips EJ, Walmsley SL. Principles of antimicrobial therapy. In Principles of Medical Pharmacology 2007 (7th Edition); 661-669.
Phillips EJ, Uetrecht J, Walmsley SL. Antimicrobial agents that act on microbial cell wall formation. In Principles of Medical Pharmacology 2007 (7th Edition); 697-711.
Uetrecht J, Phillips EJ, Walmsley SL. Antimicrobial and antifungal agents that act on cell membranes. In Principles of Medical Pharmacology 2007 (7th Edition); 689-696.
Phillips EJ, Uetrecht J, Walmsley SL. Drugs that affect cellular nucleic acid synthesis. In Principles of Medical Pharmacology 2007 (7th Edition); 712-723.
Mallal S. Complications resulting from antiretroviral therapy for HIV infection. Chapter 17. Global HIV/AIDS Medicine, editors Sande MA, Volberding P, Lange J, published by Saunders, Elsevier Inc.
Nolan D, Almeida C-A, Phillips E, Mallal S. Abacavir hypersensitivity. Drug Hypersensitivity – Karger Publishers Basel
Langan LL, D’Orsogna L, Park LP, Hughes TL, Irish A, Luxton G, Witt CS, Christiansen FT. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study. Clin Transpl 2006:219-25.
Nolan D. Chapter 24: Involvement of Apoptosis in Complications of HIV and Its Treatment (2004) In Cell Death in HIV Infection.
John M, Nolan D, Mallal SA. Lipodystrophy syndrome in the Western Australian Cohort. (2001) In AIDS Lipodystrophie Pathophysioloische Grundlagen und Klinisches Management (AIDS Lipodystrophy Pathophysiological Basis and Clinical Management) Thieme-Verlag Pty Ltd.
Martinez OP, John M, Nolan D, Mallal SA. (2002) Pathogenesis of Body Fat Redistribution and Metabolic Alterations (Spanish). In Polo Rodriguez, R (Ed). Manuel de Nutricion y SIDA (3rd edicion). NILO Industria Grafica, Spain: pp 436 – 493
Nolan DA, John M, Martinez OP, Mallal SA. (2002) Antiretroviral therapy-associated lipodystrophy: Clinical aspects and current concepts in pathogenesis. In Polo-Rodriguez, R (Ed). Textbook on Nutrition and AIDS (3rd edition). NILO Industria Grafica, Spain: pp 404-451
